Castelion Raises $1B—but Only $800M Is New Equity

Castelion unveiled a financing package in Torrance, California, that it labels a $1 billion Series C. The company’s August 19, 2026 announcement of the $1 billion financing divides it into $800 million of equity and $250 million of committed financing for a revolving credit facility.

The valuation applies to the ownership financing, not to the available credit. Axios’s August 20 transaction report identifies an $800 million Series C equity round at a $13 billion post-money valuation, accompanied by a separate $250 million revolving credit facility.

How the financing components produce the $1 billion headline

The headline amount combines two instruments with different economic effects. Only the equity component represents new capital exchanged for an ownership interest; the revolver is borrowing capacity that Castelion can access under the facility’s terms.

• Series C equity: $800 million. This is the disclosed ownership investment and the amount relevant to the round’s dilution and valuation.
• Committed revolving credit: $250 million. This is available debt financing, not evidence that the entire facility was drawn when the deal was disclosed.
• Literal total: $1.05 billion. Adding the two disclosed components produces a figure above the company’s rounded $1 billion label.

The distinction prevents two misreadings. The transaction is not $1 billion of new equity, and committed credit should not automatically be counted as cash already received. The public materials do not disclose an initial draw, so the amount borrowed at closing—if any—remains unknown.

The $13 billion valuation is tied to the equity

The post-money valuation describes the negotiated value of Castelion after the Series C equity investment. The credit commitment does not purchase shares and therefore should not be added to the equity amount when estimating the round’s ownership implications.

The disclosed numbers imply that the new equity equals roughly 6.2% of the post-money valuation, but that arithmetic is not a reliable estimate of the investors’ actual economic stake. Castelion has not published the share price, capitalization table, liquidation preferences, conversion provisions or other rights attached to the Series C securities.

TechCrunch’s account of the round names Andreessen Horowitz, Carlyle and JPMorgan Chase as co-leads and confirms that existing investors including Lightspeed, General Catalyst and Altimeter participated. Those investor names establish who backed the transaction, but the undisclosed security terms still limit what the headline valuation reveals about their protections and potential returns.

The money is financing a transition toward scaled production

The immediate industrial priority is Blackbeard, Castelion’s hypersonic strike weapon. The financing also covers development and testing of a longer-range precision-strike system and defensive systems derived from Blackbeard technologies and manufacturing methods.

Project Ranger in Sandoval County, New Mexico, is central to that production plan. The campus covers 1,000 acres, and the financing is intended to expand Blackbeard manufacturing there and beyond it. These are planned uses of capital; Castelion has not provided a dollar-by-dollar allocation between factory infrastructure, equipment, weapon development and working capital.

Contract activity provides evidence of demand, but it does not establish that full-rate production or operational fielding has occurred. Washington Technology’s August 20 coverage records more than $500 million in U.S. military contracts over the preceding 18 months, a $23.4 million Navy order for 50 Blackbeard prototypes and a framework for at least 500 missiles annually for as long as five years.

A separate development award shows how much work remains before deployment. Castelion’s February Navy contract notice details a $49,998,005 award to move Blackbeard from prototype toward integrated early operational capability, with completion expected in November 2027. That schedule describes a prospective milestone rather than a weapon already fielded at scale.

The financing instruments can support different parts of this buildout. Equity can absorb long-duration factory and development spending without scheduled principal repayment, while a revolver can cover shorter-term liquidity needs when manufacturing costs precede contract payments. No public disclosure assigns the equity and debt components to specific programs.

What remains undisclosed after the round

As of August 24, the confirmed structure is $800 million of new equity plus $250 million of committed revolving-credit capacity, with the equity round carrying a $13 billion post-money valuation. The two components explain both why the package is promoted as roughly $1 billion and why treating that entire headline as invested equity is inaccurate.

Important financing terms remain private, including the revolver’s lenders, interest rate, maturity, collateral, covenants, draw schedule and initial utilization. The rights attached to the Series C shares are also undisclosed.

The next measurable evidence will come from production and contract execution: expansion at Project Ranger, delivery of Blackbeard prototypes, progress toward early operational capability and any later disclosure of revolver usage. Until those milestones occur, available credit, planned factory capacity and targeted fielding should remain separate from equity already invested and systems already delivered.